Drug-Coated Balloons in Percutaneous Coronary Intervention: Beyond Evidence.

Drug-coated balloons (DCBs) represent a promising alternative to drug-eluting stents (DESs) by adopting a "leave-nothing-behind" approach, avoiding the long-term implantation of metallic materials associated with vessel damage, stent thrombosis, and restenosis. Although DCBs have historically been indicated for patients with in-stent restenosis or de novo small-vessel disease, recent studies indicate the potential for broader applications in acute coronary syndromes (ACSs). Trials comparing DCB and DES treatments show that DCBs yield comparable long-term outcomes, with some studies suggesting reduced rates of secondary endpoints such as cardiac death and non-fatal myocardial infarction among ACS patients treated with DCBs.

Brucella involving the heart: a hidden disease.

Brucellosis is a multisystemic disease with serious cardiac involvement mainly endocarditis. It is a lethal but rare complication involving congenital, prosthetic and even native valves. Positive hemoculture confirm the diagnosis.

Erosion of Cardiovascular Implantable Device: Conservative Therapy or Extraction?

The standard of care for device infection is normally a complete removal of the implantable system, including lead extraction in local or systemic infection cases. Despite the importance of lead extraction techniques, these techniques are complex and have some major risks. Success rates were high, but they are less favorable in patients with several comorbidities.

Fast pathway ablation in a patient with PR prolongation.

The classical form of typical atrioventricular node reentrant tachycardia (AVNRT) is a "slow-fast" pathways tachycardia, and the usual therapy is an ablation of the slow pathway since it carries a low risk of atrioventricular (AV) block. In patients with long PR interval and/or living on the anterograde slow pathway, an alternative technique is required. We report a case of a 42-year-old lady with idiopathic restrictive cardiomyopathy, persistent atrial fibrillation status post pulmonary vein isolation, and premature ventricular complex ablation with a systolic dysfunction, who presented with incessant slow narrow complex tachycardia of 110 bpm that appeared to be an AVNRT.

Lymphoma Involving the Heart: A Case Report.

We describe a rare case of cardiac malignancy that counts for <1% of the primary cardiac tumors with a poor prognosis. It's a rare case of a primary cardiac lymphoma in a 59-year-old patient who presented for recurrent pleuropericarditis with low-grade fever and night sweats. Investigations revealed an infiltrating mass in the right atrioventricular groove involving the right atrium and the right ventricular free wall.

Beta-blockers use from the general to the hemodialysis population.

Beta-blockers have numerous indications in the general population and are strongly recommended in heart failure, post-myocardial infarction and arrhythmias. In hemodialysis patients, their use is based on weak evidence because of the lack of a sufficient number of randomized clinical trials. The strongest evidence is based on two trials.

Case report: severe bradycardia, a reversible cause of "Cardio-Renal-Cerebral Syndrome".

Background: Cardio-Renal Syndromes were first classified in 2008 and divided into five subtypes. The type 1 Cardio-Renal Syndrome (CRS) is characterized by acute decompensation of heart failure leading to acute kidney injury (AKI). Bradyarrhythmia was not mentioned in the classification as a cause for low cardiac output (CO) in type 1 CRS.